Efficacy of Low‐Voltage Area Ablation Across Substrate Size in Persistent Atrial Fibrillation: A Post Hoc Analysis of the SUPPRESS‐AF Randomized Trial
Authors:
- Masato OkadaMOMasato Okada
- Daisuke SakamotoDSDaisuke Sakamoto
- Masaharu MasudaMMMasaharu Masuda
- Nobuaki TanakaNTNobuaki Tanaka
- Tetsuya WatanabeTWTetsuya Watanabe
- Hitoshi MinamiguchiHMHitoshi Minamiguchi
- Yasuyuki EgamiYEYasuyuki Egami
- Takafumi OkaTOTakafumi Oka
- Masato KawasakiMKMasato Kawasaki
- Nobuhiko MakinoNMNobuhiko Makino
- Takashi KandaTKTakashi Kanda
Open Access
- 2 June 2026
- journal article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (11) , e047814
Abstract
Background: Larger low‐voltage areas (LVAs) in the left atrium are associated with increased arrhythmia recurrence after atrial fibrillation (AF) ablation. The benefit of adjunctive LVA ablation may therefore depend on substrate extent. This study examined the efficacy of LVA ablation across a spectrum of LVA sizes in persistent AF. Methods: The SUPPRESS‐AF (Efficacy and Safety of Left Atrial Low‐Voltage Area Guided Ablation for Recurrence Prevention Compared to Pulmonary Vein Isolation Alone in Patients With Persistent Atrial Fibrillation) trial screened 1364 patients undergoing initial ablation for persistent AF, of whom 342 with left atrial LVAs (≥5 cm 2 ) were randomized to pulmonary vein isolation with or without adjunctive LVA ablation. In the 341 analyzed patients, LVA size was categorized as small (2 , n=106), moderate (≥10 to 2 , n=127), or extensive (≥20 cm 2 , n=108). The primary end point was recurrence of AF or atrial tachycardia within 1 year without antiarrhythmic drugs. Treatment effects across LVA sizes were evaluated using a Cox model with restricted cubic splines. Results: AF/atrial tachycardia recurrence rates were similar between the pulmonary vein isolation+LVA ablation and pulmonary vein isolation‐alone groups in patients with small (38.5% versus 29.6%; P =0.28) and moderate LVA sizes (40.6% versus 53.5%; P =0.15). However, adjunctive LVA ablation significantly reduced recurrence in patients with extensive LVAs (34.7% versus 57.6%; P =0.029; interaction P =0.054), driven mainly by lower AF recurrence (18.4% versus 42.4%, P =0.008). Spline analysis indicated a greater treatment benefit with increasing LVA size, reaching significance around 20 cm 2 . Conclusions: The efficacy of adjunctive LVA ablation increased with substrate size, with a significant benefit observed in patients with extensive LVAs. These findings support a substrate size–guided ablation strategy to optimize rhythm outcomes in persistent AF. Registration: URL: https://www.umin.ac.jp/ctr ; Identifier: UMIN000035940.Keywords
This publication has 31 references indexed in Scilit:
- Low-voltage-area ablation for persistent atrial fibrillation: a randomized controlled trialNature Medicine, 2025
- Artificial intelligence for individualized treatment of persistent atrial fibrillation: a randomized controlled trialNature Medicine, 2025
- Left Atrial Low Voltage Areas and Heart Failure in Patients with Atrial Fibrillation: Implication of the Atrial MyopathyESC Heart Failure, 2024
- Conduction Velocity and Anisotropic Properties of Fibrillation Waves During Acutely Induced and Long-Standing Persistent AFJACC: Clinical Electrophysiology, 2024
- Prognostic impact of atrial cardiomyopathy: Long-term follow-up of patients with and without low-voltage areas following atrial fibrillation ablationHeart Rhythm, 2023
- Decrement Evoked Potential (DEEP) Mapping of the Atria: Unmasking Atrial Fibrillation SubstrateHeart, Lung and Circulation, 2023
- Low-Voltage Myocardium-Guided Ablation Trial of Persistent Atrial FibrillationNEJM Evidence, 2022
- Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial FibrillationJAMA, 2022
- Circumferential Pulmonary Vein Isolation Plus Low-Voltage Area Modification in Persistent Atrial FibrillationJACC: Clinical Electrophysiology, 2022
- The efficacy and safety of left atrial low‐voltage area guided ablation for recurrence prevention compared to pulmonary vein isolation alone in patients with persistent atrial fibrillation trial: Design and rationaleClinical Cardiology, 2021